MX346261B - Formas polimórficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona. - Google Patents

Formas polimórficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.

Info

Publication number
MX346261B
MX346261B MX2012014277A MX2012014277A MX346261B MX 346261 B MX346261 B MX 346261B MX 2012014277 A MX2012014277 A MX 2012014277A MX 2012014277 A MX2012014277 A MX 2012014277A MX 346261 B MX346261 B MX 346261B
Authority
MX
Mexico
Prior art keywords
polymorphic forms
isoindol
dione
piperidine
dihydro
Prior art date
Application number
MX2012014277A
Other languages
English (en)
Spanish (es)
Inventor
W Muller George
Shen-Chu Chen Roger
S Jaworsky Markian
M Cameron Louise
T Saindane Manohar
Original Assignee
Celgene Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346261(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp * filed Critical Celgene Corp *
Publication of MX346261B publication Critical patent/MX346261B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
    • B65D51/2857—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it
    • B65D51/2864—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it the element being a plug or like element closing a passage between the auxiliary container and the main container
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
MX2012014277A 2003-09-04 2004-09-03 Formas polimórficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona. MX346261B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49972303P 2003-09-04 2003-09-04
PCT/US2004/028736 WO2005023192A2 (en) 2003-09-04 2004-09-03 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Publications (1)

Publication Number Publication Date
MX346261B true MX346261B (es) 2017-03-13

Family

ID=34272860

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2013002127A MX342025B (es) 2003-09-04 2004-09-03 Formas polimorficas de 3-(4-amino-1-oxo-1,3 dihidro-isoindol-2-il) -piperidin-2,6-diona.
MX2012014272A MX346260B (es) 2003-09-04 2004-09-03 Formas polimorficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.
MX2012014277A MX346261B (es) 2003-09-04 2004-09-03 Formas polimórficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.
MX2012014442A MX346372B (es) 2003-09-04 2004-09-03 Formas polimórficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.
MXPA06001994A MXPA06001994A (es) 2003-09-04 2004-09-03 Formas polimorficas de 3-(4-amino-1-oxo-1,3 dihidro-isoindol-2-il)-piperidin-2,6-diona.
MX2013006320A MX342071B (es) 2003-09-04 2006-02-21 Formas polimorficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2013002127A MX342025B (es) 2003-09-04 2004-09-03 Formas polimorficas de 3-(4-amino-1-oxo-1,3 dihidro-isoindol-2-il) -piperidin-2,6-diona.
MX2012014272A MX346260B (es) 2003-09-04 2004-09-03 Formas polimorficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2012014442A MX346372B (es) 2003-09-04 2004-09-03 Formas polimórficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.
MXPA06001994A MXPA06001994A (es) 2003-09-04 2004-09-03 Formas polimorficas de 3-(4-amino-1-oxo-1,3 dihidro-isoindol-2-il)-piperidin-2,6-diona.
MX2013006320A MX342071B (es) 2003-09-04 2006-02-21 Formas polimorficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.

Country Status (37)

Country Link
US (20) US7465800B2 (ko)
EP (7) EP3045176B8 (ko)
JP (6) JP4733037B2 (ko)
KR (3) KR20080063862A (ko)
CN (7) CN102584788A (ko)
AP (1) AP2324A (ko)
AR (2) AR047994A1 (ko)
AT (1) ATE531369T1 (ko)
AU (2) AU2004270211B2 (ko)
BR (1) BRPI0414084A (ko)
CA (9) CA2688708C (ko)
CR (2) CR8291A (ko)
CY (1) CY1112017T1 (ko)
DK (5) DK1667682T3 (ko)
EA (1) EA009922B1 (ko)
EC (1) ECSP066467A (ko)
ES (5) ES2402808T3 (ko)
GE (1) GEP20104958B (ko)
HK (6) HK1092388A1 (ko)
HR (1) HRP20110836T1 (ko)
HU (3) HUE041265T2 (ko)
IL (5) IL174067A (ko)
IS (1) IS8340A (ko)
MA (1) MA28084A1 (ko)
ME (3) ME01571B (ko)
MX (6) MX342025B (ko)
NO (4) NO336898B1 (ko)
NZ (1) NZ546054A (ko)
OA (1) OA13250A (ko)
PE (1) PE20060284A1 (ko)
PL (5) PL2426118T3 (ko)
PT (5) PT3042659T (ko)
RS (3) RS53104B (ko)
SI (2) SI1667682T1 (ko)
UA (1) UA83504C2 (ko)
WO (1) WO2005023192A2 (ko)
ZA (1) ZA200601858B (ko)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
ES2290091T3 (es) * 2000-11-30 2008-02-16 The Children's Medical Center Corporation Sintesis de enantiomeros de 4-amino-talidomida.
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
MXPA06012278A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
JP5366544B2 (ja) * 2005-06-30 2013-12-11 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法
KR20080026198A (ko) * 2005-06-30 2008-03-24 안트로제네시스 코포레이션 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
EP1919500A2 (en) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
EP1919365A2 (en) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Ocular plug formed from placenta derived collagen biofabric
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
WO2008042441A1 (en) * 2006-10-03 2008-04-10 Anthrogenesis Corporation Use of umbilical cord biomaterial for ocular surgery
WO2008060377A2 (en) 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
NZ597223A (en) 2006-10-06 2013-09-27 Anthrogenesis Corp Native (telopeptide) placental collagen compositions
KR101955140B1 (ko) 2007-09-28 2019-03-06 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
US7964354B2 (en) * 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
KR20100124710A (ko) * 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
AU2009321374A1 (en) * 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
WO2010056384A1 (en) * 2008-11-17 2010-05-20 Dr. Reddy's Laboratories Ltd. Lenalidomide solvates and processes
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
CN102414196A (zh) 2009-03-02 2012-04-11 基因里克斯(英国)有限公司 改进的方法
WO2010129636A2 (en) * 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lenalidomide polymorph
BRPI1007855B1 (pt) 2009-05-19 2020-03-10 Celgene Corporation Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
CN101665484B (zh) * 2009-07-20 2012-11-21 上海皓元生物医药科技有限公司 一种制备来那度胺的方法
MX2012001890A (es) 2009-08-12 2012-03-26 Synthon Bv Sales de lenalidomida.
PL2477973T3 (pl) 2009-09-16 2015-04-30 Ranbaxy Laboratories Ltd Sposób wytwarzania krystalicznej formy lenalidomidu
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN101696205B (zh) * 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102060842B (zh) * 2009-11-02 2013-05-08 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of form b of lenalidomide
WO2011069608A1 (en) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
KR20130038232A (ko) * 2010-03-08 2013-04-17 낫코 파마 리미티드 무수 레날리도마이드 ｆｏｒｍ-ｉ
US9193989B2 (en) 2010-06-18 2015-11-24 Taiho Pharmaceutical Co., Ltd. PRPK-TPRKB modulators and uses thereof
US9918197B2 (en) 2010-10-04 2018-03-13 Lazo Inc. Interactive advertisement environment
US20140031325A1 (en) 2010-12-06 2014-01-30 Celgene Corporation Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
CN102070606A (zh) * 2011-02-17 2011-05-25 江苏先声药物研究有限公司 一种雷利度胺a晶型新的制备方法
CN102643266B (zh) * 2011-02-17 2015-02-18 江苏先声药物研究有限公司 一种雷利度胺b晶型的制备方法
AR085650A1 (es) 2011-03-11 2013-10-16 Celgene Corp Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y usos
WO2012127493A1 (en) 2011-03-23 2012-09-27 Hetero Research Foundation Polymorphs of lenalidomide
CA2867134C (en) 2011-03-28 2019-05-07 Sheila Dewitt 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
WO2014066243A1 (en) * 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2953635A4 (en) 2013-02-05 2016-10-26 Anthrogenesis Corp NATURAL KILLER CELLS FROM PLAZENTA
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
CN104072476B (zh) * 2013-03-27 2018-08-21 江苏豪森药业集团有限公司 泊马度胺晶型及其制备方法和用途
EP2981532A4 (en) * 2013-04-01 2016-12-14 Hetero Research Foundation PROCESS FOR THE PREPARATION OF POMALIDOMIDE
EP3869361A1 (en) * 2013-09-03 2021-08-25 Fugro Chance, Inc. Interactive remote guidance system for seaborne vessels
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
EP2875817B1 (en) * 2013-11-26 2020-03-18 Synhton B.V. Pharmaceutical formulation comprising amorphous lenalidomide
AU2015210999A1 (en) 2014-01-29 2016-07-21 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
CN104016966A (zh) * 2014-01-30 2014-09-03 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
WO2015113314A1 (zh) * 2014-01-30 2015-08-06 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
CN106456634A (zh) * 2014-04-22 2017-02-22 大塚制药株式会社 布雷帕唑和纳美芬的组合及其用于治疗物质有关的病症的用途
CN105085473B (zh) * 2014-04-24 2019-06-18 江苏豪森药业集团有限公司 来那度胺晶型及其制备方法和医药用途
US20170107193A1 (en) * 2014-04-26 2017-04-20 Shilpa Medicare Limited Crystalline lenalidomide process
US10025472B2 (en) * 2014-06-01 2018-07-17 Apple Inc. Method and apparatus for displaying data regarding a device's traversal through a region
US10392364B2 (en) 2014-08-11 2019-08-27 Avra Laboratories Pvt. Ltd. Process for synthesis of lenalidomide
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US9794331B1 (en) * 2014-09-29 2017-10-17 Amazon Technologies, Inc. Block allocation based on server utilization
EP3233059A1 (en) 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
US10471156B2 (en) 2014-12-19 2019-11-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
CN104610210B (zh) * 2015-02-05 2017-06-16 天津大学 一种脱氢醋酸钠无水物制备方法
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
ES2811110T3 (es) 2015-08-27 2021-03-10 Grindeks Jsc Composición farmacéutica capaz de la incorporación de Lenalidomida en diversas modificaciones cristalinas
WO2017109041A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
RU2616976C1 (ru) * 2016-04-07 2017-04-19 Олег Ростиславович Михайлов Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
TWI664172B (zh) * 2016-08-25 2019-07-01 大陸商浙江海正藥業股份有限公司 來那度胺的晶型及其製備方法和用途
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN108658935A (zh) * 2017-03-27 2018-10-16 天津大学 来那度胺新晶型、其制备方法及其医药用途
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
CN112062751A (zh) * 2017-08-04 2020-12-11 正大天晴药业集团股份有限公司 一种来那度胺的新结晶及其药物组合物
US20200254093A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
EP3700508A1 (en) 2017-10-26 2020-09-02 Synbias Pharma AG Lenalidomide immediate release formulations
EP3505158A1 (en) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
CN108191826A (zh) * 2018-01-08 2018-06-22 浙江省医学科学院 一种来那度胺晶体及其制备方法
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019138424A1 (en) 2018-01-11 2019-07-18 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
CN108840908A (zh) * 2018-07-10 2018-11-20 刘凤娟 特拉匹韦的一种新晶型及其制备方法
CN111217792B (zh) * 2018-11-23 2021-09-28 欣凯医药化工中间体（上海）有限公司 一种来那度胺b晶型的制备方法
JP2024503001A (ja) 2021-01-08 2024-01-24 スタートン セラピューティクス インコーポレイテッド 非経口用の免疫調節イミド化合物の安定溶液
WO2023126530A1 (en) 2021-12-31 2023-07-06 A Fine House S.A. Oral solution comprising lenalidomide
WO2023126531A1 (en) 2021-12-31 2023-07-06 A Fine House S.A. Lenalidomide oral solution

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU690377B2 (en) * 1994-11-04 1998-04-23 Polymun Scientific Immunobiologische Forschung Gmbh Application of superoxide dismutase in liposomes
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
DE19601303A1 (de) 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ATE229521T3 (de) * 1996-07-24 2002-12-15 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5929117A (en) 1996-08-12 1999-07-27 Celgene Corporation Immunotherapeutic agents
PT1920773E (pt) 1996-11-05 2011-01-27 Childrens Medical Center Composições para a inibição de angiogénese
AU5875598A (en) 1997-02-05 1998-08-26 University Of Hertfordshire Preparation of spheroids and their use in medicin or diagnosis
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101500T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
ATE306469T1 (de) 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CA2319872C (en) 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
TR200202194T2 (tr) 2000-03-17 2003-01-21 Cell Therapeutics, Inc. Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
AU2001249755A1 (en) 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
CA2408707C (en) 2000-05-15 2010-04-13 Celgene Corp. Compositions and methods for the treatment of cancer
AU9123201A (en) * 2000-09-26 2002-04-08 Reddy S Res Foundation Novel polymorphic forms of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione maleate and process for their preparation
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
ES2290091T3 (es) 2000-11-30 2008-02-16 The Children's Medical Center Corporation Sintesis de enantiomeros de 4-amino-talidomida.
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
DE60231989D1 (de) 2001-08-06 2009-05-28 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2003086373A1 (en) 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP1505973B1 (en) 2002-05-17 2010-03-03 Celgene Corporation Combinations for treating multiple myeloma
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2004001004A1 (es) 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1675857B1 (en) * 2003-10-22 2011-07-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
AU2005282728A1 (en) * 2004-09-03 2006-03-16 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
US20090092343A1 (en) * 2007-10-05 2009-04-09 Mary Thomson Locking Bag with Locking Handle
KR20100124710A (ko) * 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
WO2009111948A1 (zh) 2008-03-13 2009-09-17 天津和美生物技术有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
WO2010019435A2 (en) 2008-08-14 2010-02-18 Teva Pharmaceutical Industries Ltd. Solid states of atorvastatin potassium
AU2009321374A1 (en) * 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
WO2010056384A1 (en) 2008-11-17 2010-05-20 Dr. Reddy's Laboratories Ltd. Lenalidomide solvates and processes
CN102414196A (zh) 2009-03-02 2012-04-11 基因里克斯(英国)有限公司 改进的方法
WO2010129636A2 (en) 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lenalidomide polymorph
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
MX2012001890A (es) 2009-08-12 2012-03-26 Synthon Bv Sales de lenalidomida.
CA2773012A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
PL2477973T3 (pl) 2009-09-16 2015-04-30 Ranbaxy Laboratories Ltd Sposób wytwarzania krystalicznej formy lenalidomidu
TWI475014B (zh) 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of form b of lenalidomide
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
WO2011069608A1 (en) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
KR20130038232A (ko) 2010-03-08 2013-04-17 낫코 파마 리미티드 무수 레날리도마이드 ｆｏｒｍ-ｉ
CN101791288B (zh) 2010-04-07 2011-12-28 南京卡文迪许生物工程技术有限公司 一种稳定的来那度胺口服固体制剂
CN102453021A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 来那度胺的新晶型及其制备方法

Also Published As

Publication number Publication date
US7465800B2 (en) 2008-12-16
US20200239431A1 (en) 2020-07-30
CA2687927C (en) 2012-05-29
EP3045176B8 (en) 2018-12-12
ATE531369T1 (de) 2011-11-15
ES2718927T3 (es) 2019-07-05
HUE042071T2 (hu) 2019-06-28
CR10967A (es) 2009-12-10
US20190218201A1 (en) 2019-07-18
AR102756A2 (es) 2017-03-22
US11655232B2 (en) 2023-05-23
CA2688709C (en) 2011-08-09
NO336898B1 (no) 2015-11-23
CA2688695C (en) 2011-08-09
JP2013209407A (ja) 2013-10-10
US8143286B2 (en) 2012-03-27
CN101838261A (zh) 2010-09-22
US9365538B2 (en) 2016-06-14
CA2687924A1 (en) 2005-03-17
IL225791A0 (en) 2013-06-27
KR100979869B1 (ko) 2010-09-02
IL174067A0 (en) 2006-08-01
US7855217B2 (en) 2010-12-21
MX346372B (es) 2017-03-16
US20050096351A1 (en) 2005-05-05
EP3045176B1 (en) 2018-11-07
US8431598B2 (en) 2013-04-30
AU2004270211A1 (en) 2005-03-17
CA2537092A1 (en) 2005-03-17
MX346260B (es) 2017-03-13
US9353080B2 (en) 2016-05-31
SI2426118T1 (sl) 2013-06-28
ECSP066467A (es) 2006-09-18
CA2537092C (en) 2011-08-09
BRPI0414084A (pt) 2006-10-24
US20180072700A1 (en) 2018-03-15
US20120022106A1 (en) 2012-01-26
CN102060843B (zh) 2013-08-14
PT2426118E (pt) 2013-04-04
US20170121304A1 (en) 2017-05-04
PT3045176T (pt) 2019-02-04
HK1167646A1 (ko) 2012-12-07
KR20060087543A (ko) 2006-08-02
US20110288127A1 (en) 2011-11-24
EP3045175A1 (en) 2016-07-20
EP3045175B8 (en) 2018-12-19
CN1871003B (zh) 2012-03-14
US20120029020A1 (en) 2012-02-02
HK1157772A1 (ko) 2012-07-06
CN1871003A (zh) 2006-11-29
CA2687927A1 (en) 2005-03-17
EA009922B1 (ru) 2008-04-28
NO20061528L (no) 2006-06-02
OA13250A (en) 2007-01-31
NO20161012A1 (no) 2016-06-15
HK1148274A1 (ko) 2011-09-02
US20220127244A1 (en) 2022-04-28
PT3042659T (pt) 2019-02-04
RS53104B (en) 2014-06-30
IS8340A (is) 2006-03-07
PL1667682T3 (pl) 2012-04-30
US20090062343A1 (en) 2009-03-05
JP5925418B2 (ja) 2016-05-25
ME01572B (me) 2014-09-20
HRP20110836T1 (hr) 2011-12-31
PL3042659T3 (pl) 2019-04-30
ES2402808T3 (es) 2013-05-09
US7977357B2 (en) 2011-07-12
IL225792A0 (en) 2013-06-27
DK3042659T3 (en) 2019-02-25
EP3045175B1 (en) 2018-11-07
KR101005991B1 (ko) 2011-01-05
CA2688708C (en) 2011-08-09
US11136306B2 (en) 2021-10-05
DK1667682T3 (da) 2011-12-12
US20120029019A1 (en) 2012-02-02
NO20150253L (no) 2006-06-02
JP2011137024A (ja) 2011-07-14
UA83504C2 (en) 2008-07-25
AU2009200257A1 (en) 2009-02-19
US20170121305A1 (en) 2017-05-04
EP2426118B1 (en) 2013-01-23
US20090149499A1 (en) 2009-06-11
AU2009200257B2 (en) 2012-02-02
CN102060843A (zh) 2011-05-18
US8193219B2 (en) 2012-06-05
CA2741412A1 (en) 2005-03-17
IL207458A (en) 2015-08-31
HUE041265T2 (hu) 2019-05-28
EP3042659A1 (en) 2016-07-13
DK3045175T3 (en) 2019-03-04
JP4733037B2 (ja) 2011-07-27
EP2425836A1 (en) 2012-03-07
RS20120339A1 (en) 2013-04-30
EP3042659B8 (en) 2018-12-19
RS20120340A1 (en) 2013-04-30
CA2688709A1 (en) 2005-03-17
PT3045175T (pt) 2019-02-04
JP6200977B2 (ja) 2017-09-20
JP5309104B2 (ja) 2013-10-09
PL3045175T3 (pl) 2019-04-30
CY1112017T1 (el) 2015-11-04
EP3045176A1 (en) 2016-07-20
CN102675281A (zh) 2012-09-19
EP3459544A1 (en) 2019-03-27
DK3045176T3 (en) 2019-02-25
ES2718925T3 (es) 2019-07-05
HUE041282T2 (hu) 2019-05-28
CN102584788A (zh) 2012-07-18
US20160009684A1 (en) 2016-01-14
CA2687924C (en) 2011-08-09
ES2376879T3 (es) 2012-03-20
HK1202531A1 (en) 2015-10-02
US20090176832A1 (en) 2009-07-09
JP2014094957A (ja) 2014-05-22
ME01530B (me) 2011-10-10
KR20090086647A (ko) 2009-08-13
US8822499B2 (en) 2014-09-02
PT1667682E (pt) 2012-01-19
CA2688694C (en) 2011-08-09
CA2741412C (en) 2013-07-16
AU2004270211B2 (en) 2008-10-23
NO341039B1 (no) 2017-08-14
WO2005023192A2 (en) 2005-03-17
WO2005023192A3 (en) 2005-09-29
ZA200601858B (en) 2007-07-25
US8058443B2 (en) 2011-11-15
MA28084A1 (fr) 2006-08-01
IL174067A (en) 2015-07-30
NO20160131A1 (no) 2016-01-28
CN101863878B (zh) 2012-07-18
AP2006003558A0 (en) 2006-04-30
CN101863878A (zh) 2010-10-20
CN101838261B (zh) 2013-07-10
EP2426118A1 (en) 2012-03-07
EP1667682A2 (en) 2006-06-14
JP2011006470A (ja) 2011-01-13
NO337446B1 (no) 2016-04-11
US9371309B2 (en) 2016-06-21
PE20060284A1 (es) 2006-04-13
MXPA06001994A (es) 2006-05-31
HK1148974A1 (ko) 2011-09-23
SI1667682T1 (sl) 2011-12-30
RS20060158A (en) 2008-08-07
HK1092388A1 (ko) 2007-02-09
ES2718926T3 (es) 2019-07-05
EP1667682A4 (en) 2009-05-06
CA2741575A1 (en) 2005-03-17
NZ546054A (en) 2009-12-24
PL2426118T3 (pl) 2013-08-30
MX342025B (es) 2016-09-12
MX342071B (es) 2016-09-13
US20120046316A1 (en) 2012-02-23
IL238911A0 (en) 2015-06-30
EP3042659B1 (en) 2018-11-07
DK2426118T3 (da) 2013-03-25
KR20080063862A (ko) 2008-07-07
ME01571B (me) 2014-09-20
CA2741575C (en) 2013-07-16
US20170121303A1 (en) 2017-05-04
EA200600535A1 (ru) 2006-08-25
PL3045176T3 (pl) 2019-04-30
EP1667682B1 (en) 2011-11-02
CA2688695A1 (en) 2005-03-17
US20090149500A1 (en) 2009-06-11
JP2016074734A (ja) 2016-05-12
NO341035B1 (no) 2017-08-07
US20090187023A1 (en) 2009-07-23
CR8291A (es) 2007-09-17
US20110015228A1 (en) 2011-01-20
CN102675281B (zh) 2016-01-20
CA2688708A1 (en) 2005-03-17
AR047994A1 (es) 2006-03-15
CN104059052A (zh) 2014-09-24
AP2324A (en) 2011-11-21
GEP20104958B (en) 2010-04-26
JP2007504248A (ja) 2007-03-01
US10590104B2 (en) 2020-03-17
CA2688694A1 (en) 2005-03-17
IL207458A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
MX342071B (es) Formas polimorficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona.
CY1113926T1 (el) Μεθοδος κατασκευης πολυμορφικων μορφων 3-(4-αμινο-1-οξο-1,3-διϋδρο-ισοϊνδολ-2-υλ)-πιπεριδινο-2,6-διονης
AU2013203194B9 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione